Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
| Title: | Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. |
|---|---|
| Authors: | Tan SHX; From the Saw Swee Hock School of Public Health (S.H.X.T., A.R.C., D.H., K.B.T.) and the Yong Loo Lin School of Medicine (D.C.L.), National University of Singapore, the Ministry of Health (D.H., B.O., K.B.T.), the National Centre for Infectious Diseases (D.C.L.), Tan Tock Seng Hospital (D.C.L.), the Lee Kong Chian School of Medicine, Nanyang Technological University (D.C.L.), and the Centre of Regulatory Excellence, Duke-National University of Singapore Medical School (K.B.T.) - all in Singapore.; Cook AR; From the Saw Swee Hock School of Public Health (S.H.X.T., A.R.C., D.H., K.B.T.) and the Yong Loo Lin School of Medicine (D.C.L.), National University of Singapore, the Ministry of Health (D.H., B.O., K.B.T.), the National Centre for Infectious Diseases (D.C.L.), Tan Tock Seng Hospital (D.C.L.), the Lee Kong Chian School of Medicine, Nanyang Technological University (D.C.L.), and the Centre of Regulatory Excellence, Duke-National University of Singapore Medical School (K.B.T.) - all in Singapore.; Heng D; From the Saw Swee Hock School of Public Health (S.H.X.T., A.R.C., D.H., K.B.T.) and the Yong Loo Lin School of Medicine (D.C.L.), National University of Singapore, the Ministry of Health (D.H., B.O., K.B.T.), the National Centre for Infectious Diseases (D.C.L.), Tan Tock Seng Hospital (D.C.L.), the Lee Kong Chian School of Medicine, Nanyang Technological University (D.C.L.), and the Centre of Regulatory Excellence, Duke-National University of Singapore Medical School (K.B.T.) - all in Singapore.; Ong B; From the Saw Swee Hock School of Public Health (S.H.X.T., A.R.C., D.H., K.B.T.) and the Yong Loo Lin School of Medicine (D.C.L.), National University of Singapore, the Ministry of Health (D.H., B.O., K.B.T.), the National Centre for Infectious Diseases (D.C.L.), Tan Tock Seng Hospital (D.C.L.), the Lee Kong Chian School of Medicine, Nanyang Technological University (D.C.L.), and the Centre of Regulatory Excellence, Duke-National University of Singapore Medical School (K.B.T.) - all in Singapore.; Lye DC; From the Saw Swee Hock School of Public Health (S.H.X.T., A.R.C., D.H., K.B.T.) and the Yong Loo Lin School of Medicine (D.C.L.), National University of Singapore, the Ministry of Health (D.H., B.O., K.B.T.), the National Centre for Infectious Diseases (D.C.L.), Tan Tock Seng Hospital (D.C.L.), the Lee Kong Chian School of Medicine, Nanyang Technological University (D.C.L.), and the Centre of Regulatory Excellence, Duke-National University of Singapore Medical School (K.B.T.) - all in Singapore.; Tan KB; From the Saw Swee Hock School of Public Health (S.H.X.T., A.R.C., D.H., K.B.T.) and the Yong Loo Lin School of Medicine (D.C.L.), National University of Singapore, the Ministry of Health (D.H., B.O., K.B.T.), the National Centre for Infectious Diseases (D.C.L.), Tan Tock Seng Hospital (D.C.L.), the Lee Kong Chian School of Medicine, Nanyang Technological University (D.C.L.), and the Centre of Regulatory Excellence, Duke-National University of Singapore Medical School (K.B.T.) - all in Singapore. |
| Source: | The New England journal of medicine [N Engl J Med] 2022 Aug 11; Vol. 387 (6), pp. 525-532. Date of Electronic Publication: 2022 Jul 20. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Boston, Massachusetts Medical Society. |
| MeSH Terms: | BNT162 Vaccine*/pharmacology ; BNT162 Vaccine*/therapeutic use ; COVID-19*/epidemiology ; COVID-19*/prevention & control ; COVID-19*/virology ; SARS-CoV-2*/drug effects ; SARS-CoV-2*/genetics ; Vaccine Efficacy*/statistics & numerical data; Hospitalization/statistics & numerical data ; Singapore/epidemiology ; Viral Vaccines/pharmacology ; Viral Vaccines/therapeutic use ; Child ; Child, Preschool ; Humans |
| Abstract: | Background: Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant in children are lacking.; Methods: In a study conducted from January 21, 2022, through April 8, 2022, when the omicron variant was spreading rapidly, we analyzed data on children in Singapore who were 5 to 11 years of age. We assessed the incidences of all reported SARS-CoV-2 infections (confirmed on polymerase-chain-reaction [PCR] assay, rapid antigen testing, or both), SARS-CoV-2 infections confirmed on PCR assay, and coronavirus disease 2019 (Covid-19)-related hospitalizations among unvaccinated, partially vaccinated (≥1 day after the first dose of vaccine and up to 6 days after the second dose), and fully vaccinated children (≥7 days after the second dose). Poisson regression was used to estimate vaccine effectiveness from the incidence rate ratio of outcomes.; Results: A total of 255,936 children were included in the analysis. Among unvaccinated children, the crude incidence rates of all reported SARS-CoV-2 infections, PCR-confirmed SARS-CoV-2 infections, and Covid-19-related hospitalizations were 3303.5, 473.8, and 30.0 per 1 million person-days, respectively. Among partially vaccinated children, vaccine effectiveness was 13.6% (95% confidence interval [CI], 11.7 to 15.5) against all SARS-CoV-2 infections, 24.3% (95% CI, 19.5 to 28.9) against PCR-confirmed SARS-CoV-2 infection, and 42.3% (95% CI, 24.9 to 55.7) against Covid-19-related hospitalization; in fully vaccinated children, vaccine effectiveness was 36.8% (95% CI, 35.3 to 38.2), 65.3% (95% CI, 62.0 to 68.3), and 82.7% (95% CI, 74.8 to 88.2), respectively.; Conclusions: During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19-related hospitalization among children 5 to 11 years of age.; (Copyright © 2022 Massachusetts Medical Society.) |
| References: | N Engl J Med. 2021 Jul 15;385(3):239-250. (PMID: 34043894); MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. (PMID: 35085224); MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. (PMID: 35176007); N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250); Nature. 2022 Feb 4;:. (PMID: 35121816); Cell. 2021 Nov 11;184(23):5699-5714.e11. (PMID: 34735795); Nat Med. 2022 Jan;28(1):193-200. (PMID: 34931076); Lancet. 2021 Dec 11;398(10317):2126-2128. (PMID: 34871545); MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):429-436. (PMID: 35298458); MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):352-358. (PMID: 35239634); Lancet Reg Health Am. 2023 May;21:100487. (PMID: 37155483); Vaccines (Basel). 2021 Nov 30;9(12):. (PMID: 34960161); N Engl J Med. 2022 May 19;386(20):1899-1909. (PMID: 35353976); J Korean Med Sci. 2022 Feb 07;37(5):e35. (PMID: 35132841); Int J Environ Res Public Health. 2020 Nov 16;17(22):. (PMID: 33207689); Cell. 2022 Feb 3;185(3):447-456.e11. (PMID: 35026151); Nature. 2022 Feb;602(7898):671-675. (PMID: 35016199); MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428. (PMID: 35298453); Int J Infect Dis. 2022 Mar;116:38-42. (PMID: 34971823); Int J Environ Res Public Health. 2021 Jul 29;18(15):. (PMID: 34360345); Arch Dis Child. 2020 Dec 1;:. (PMID: 33262177); Am J Trop Med Hyg. 2021 Jun 15;105(2):413-420. (PMID: 34129517); N Engl J Med. 2021 Oct 7;385(15):1393-1400. (PMID: 34525275); N Engl J Med. 2022 Jan 6;386(1):35-46. (PMID: 34752019); JAMA. 2021 Mar 16;325(11):1074-1087. (PMID: 33625505); Lancet Child Adolesc Health. 2021 Oct;5(10):708-718. (PMID: 34358472); Int J Environ Res Public Health. 2021 Mar 26;18(7):. (PMID: 33810225); Emerg Microbes Infect. 2022 Dec;11(1):337-343. (PMID: 34935594); PLoS Comput Biol. 2021 Feb 11;17(2):e1008559. (PMID: 33571188); MMWR Morb Mortal Wkly Rep. 2022 Apr 22;71(16):574-581. (PMID: 35446827) |
| Substance Nomenclature: | 0 (BNT162 Vaccine); 0 (Viral Vaccines) |
| SCR Organism: | SARS-CoV-2 variants |
| Entry Date(s): | Date Created: 20220720 Date Completed: 20220812 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9342421 |
| DOI: | 10.1056/NEJMoa2203209 |
| PMID: | 35857701 |
| Database: | MEDLINE |
Journal Article